irbesartan brands

48 registered brands containing irbesartan in Kenya.

Irbesartan

PubChem CID 3749

Molecular formula: C25H28N6O

Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland. Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor. Irbesartan's prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure. Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure. Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth. Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 angiotensin II receptor. There is also an AT2 receptor in many tissues, but it is not involved in cardiovascular homeostasis. Irbesartan is a specific competitive antagonist of AT1 receptors with a much greater affinity (more than 8500-fold) for the AT1 receptor than for the AT2 receptor and no agonist activity. Blockade of the AT1 receptor removes the negative feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and circulating angiotensin II do not overcome the effects of irbesartan on blood pressure. Irbesartan does not inhibit ACE or renin or affect other hormone receptors or ion channels known to be involved in the cardiovascular regulation of blood pressure and sodium homeostasis. Because irbesartan does not inhibit ACE, it does not affect the response to bradykinin; whether this has clinical relevance is not known.

Source: PubChem (NCBI) · compound 3749

Product Manufacturer Status Country
AMLOARB 10 TABLETS
IRBESARTAN BP 300MG AND AMLODIPINE (AS BESYLATE) 10.0MG PER TABLET.
Dawa Registered Kenya
AMLOARB 5 TABLETS
IRBESARTAN 300MG & AMLODIPINE (AS BESYLATE) 5MG PER TABLET.
Dawa Registered Kenya
ANDARAN
300MG
Sandoz Registered Kenya
ANDARAN
150MG
Sandoz Registered Kenya
ANDARAN
75MG
Sandoz Registered Kenya
ANDARAN HCT
300MG/12.5MG
Nvs Kenya - Kenya
ANDARAN HCT
150MG/12.5MG
Nvs Kenya Withdrawn Kenya
APROVASC 150MG/10MG TABLET
150MG / 10MG
Ressourcethica Registered Kenya
APROVASC 150MG/5MG TABLET
150MG/5MG
Ressourcethica Registered Kenya
APROVASC 300MG/10MG TABLET
IRBESARTAN / AMLODIPINE BESYLATE
Ressourcethica Registered Kenya
APROVASC 300MG/5MG TABLET
300MG / 5MG
Ressourcethica Registered Kenya
APROVEL 150MG TABLET
150MG
Ressourcethica Registered Kenya
Aprovel 150mg tablet
Tablet
Sanofi-aventis Kenya Retained Kenya
APROVEL 300MG TABLET
300MG
Ressourcethica Registered Kenya
ARBI 150MG TABLET
IRBESARTAN 150 MG
Harleys Registered Kenya
ARBI 300MG TABLET
IRBESARTAN 300 MG
Harleys Registered Kenya
ARBI-D 150/12.5MG TABLET
IRBESARTAN 150 MG, HYDROCHLOROTHIAZIDE 12.5 MG
Harleys Registered Kenya
CO-APROVEL 150MG/12.5MG TABLET
IRBESARTAN 150MG + HYDROCHLOROTHIAZIDE 12.5MG
Ressourcethica Registered Kenya
CO-APROVEL 300MG/12.5MG TABLET
IRBESARTAN 300MG + HYDROCHLOROTHIAZIDE 12.5MG
Ressourcethica Registered Kenya
CO-APROVEL 300MG/25MG TABLET
IRBESARTAN 300MG + HYDROCHLOROTHIAZIDE 25MG
Ressourcethica Registered Kenya
CONVERIUM 150G
IRBERSARTAN 150MG
Sunpar Pharmaceuticals Registered Kenya
CONVERIUM 300MG
IRBESARTAN 300MG
Sunpar Pharmaceuticals Registered Kenya
CORYCARDON 150/12.5MG TABLETS
150/12.5MG
Europa Healthcare Registered Kenya
CORYCARDON 300/12.5MG TABLETS
300/12.5MG
Europa Healthcare Registered Kenya
IRBETAN 150
IRBESARTAN USP 150MG
Surgilinks Registered Kenya
IRBETAN 300
IRBESARTAN USP 300MG
Surgilinks Registered Kenya
IRBETAN-H
IRBESARTAN USP 150 MG & HYDROCHLOROTHIAZIDE BP12.5 MG
Surgilinks Registered Kenya
IRBIS 150
EACH FILM COATED TABLET CONTAINS 150 MG OF IRBESARTAN PH.EUR
Unisel Registered Kenya
IRBIS 300
EACH FILM COATED TABLET CONTAINS 300 MG OF IRBESARTAN PH.EUR
Unisel Registered Kenya
IRBIS 75
EACH FILM COATED TABLET CONTAINS 75 MG OF IRBESARTAN PH.EUR
Unisel Registered Kenya
IRBIS-HT 150/12.5
IRBESARTAN PH.EUR 150 MG, HYDROCHLOROTHIAZIDE PH.EUR 12.5 MG
Unisel Registered Kenya
IRBIS-HT 300/12.5
IRBESARTAN 300 MG AND HYDROCHLOROTHIAZIDE 12.5 MG
Unisel Registered Kenya
IROVEL 150MG TABLETS
150 MG
Sun Pharma Registered Kenya
IROVEL 150MG TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
IROVEL 150MG TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
IROVEL 300MG TABLETS
300 MG
Sun Pharma Registered Kenya
IROVEL 300MG TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
IROVEL 300MG TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
IROVEL H TABLETS
IRBESARTAN - 150 MG HYDROCHLOROTHIAZIDE - 12.5 MG
Sun Pharma Registered Kenya
IROVEL H TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
IROVEL H TABLETS
Tablet
Sun Pharmaceutical Industries Limited Retained Kenya
MEDISART H TABLETS
IRBESARTAN USP 150MGS HYDROCHLOROTHIAZIDE 12.5MGS
Medistar Pharmaceuticals Registered Kenya
MEDISART TABLETS
150MG
Medistar Pharmaceuticals Registered Kenya
RYCARDON 150MG TABLETS
150MG
Europa Healthcare Registered Kenya
RYCARDON 300MG TABLETS
300MG
Europa Healthcare Registered Kenya
VIVAZAC® 300MG F/C TABLETS
EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 300MG
Evka Consultz Registered Kenya
VIVAZAC® PLUS (150/12.5) MG F/C TABLETS
EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 150MG AND HYDROCHLOROTHIAZIDE PH EUR 12.5MG
Evka Consultz Registered Kenya
VIVAZAC® PLUS (300/25) MG F/C TABLETS
EACH FILM COATED TABLET CONTAINS: IRBESARTAN PH EUR 300MG AND HYDROCHLOROTHIAZIDE PH EUR 25MG
Evka Consultz Registered Kenya